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Abstract 
Background: Case management based on prompt diagnosis and adequate treatment using artemisinin‑based 
combination therapy (ACT) remains the main focus of malaria control in Ghana. As part of routine surveillance on the 
therapeutic efficacy of ACT in Ghana, the efficacy of amodiaquine‑artesunate (AS‑AQ) and artemether‑lumefantrine 
(AL) were studied in six sentinel sites representing the forest and savannah zones of the country.
Methods: Three sites representing the two ecological zones studied AS‑AQ whilst the other three sites studied 
AL. In each site, the study was a one‑arm prospective evaluation of the clinical, parasitological, and haematological 
responses to directly observed therapy for uncomplicated malaria with either AS‑AQ or AL among children aged 
6 months and 9 years. The WHO 2009 protocol for monitoring anti‑malarial drug efficacy was used for the study 
between July 2013 and March 2014.
Results: Per‑protocol analyses on day 28 showed an overall PCR‑corrected cure rate of 100 % for AS‑AQ and 97.6 % 
(95 % CI 93.1, 99.5) for AL: 97.2 % (95 % CI 92.0, 99.4) in the forest zone and 100 % in the savannah zone. Kaplan–Meier 
survival analysis showed similar outcomes. Prevalence of fever decreased by about 75 % after the first day of treat‑
ment with each ACT in the two ecological zones. No child studied was parasitaemic on day 3, and gametocytaemia 
was generally maintained at low levels (<5 %). Post‑treatment mean haemoglobin concentrations significantly 
increased in the two ecological zones.
Conclusions: Therapeutic efficacy of AS‑AQ and AL remains over 90 % in the forest and savannah zones of Ghana. 
Additionally, post‑treatment parasitaemia on day 3 is rare suggesting that artemisinin is still efficacious in Ghana.
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Background
Malaria remains a major public health problem in the 
world after decades of deployment of different inter-
ventions. Globally, an estimated 3.3 billion people are 
at risk of malaria infection and disease. It is estimated 
that in 2013 there were approximately 198 million cases 
of malaria worldwide, representing a decline of 30  % 
since year 2000. In the same year, malaria accounted for 
approximately 584,000 deaths worldwide, representing a 
decline of 47 % since year 2000. Africa remains the conti-
nent with the heaviest burden of malaria, accounting for 
about 90  % of all malaria deaths in the world. It is also 
estimated that about 78  % of all malaria deaths occur 
among children aged under 5 years [1]. In 2013, malaria 
was estimated to account for 44 % of all outpatient clinic 
visits and 22.3 % of all under-five deaths in Ghana [2].
Case management based on prompt diagnosis and ade-
quate treatment remains a major focus of malaria control 
in Ghana. Other interventions include intermittent pre-
ventive treatment among pregnant women (IPTp), long-
lasting insecticide-treated nets (LLINs), indoor residual 
spraying (IRS), and recently seasonal malaria chemopre-
vention (SMC) [3]. Evidence of the declining efficacy of 
chloroquine from 1998 to 2003, and the superiority of 
artemisnin-based combination therapy (ACT) resulted in 
the replacement of chloroquine with artesunate-amodi-
aquine (AS-AQ) combination in 2005 as first-line treat-
ment for uncomplicated malaria in Ghana [4–6]. In 2008, 
artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DHAP) were added as alternative first-line 
drugs for patients unable to tolerate AS-AQ [7].
Since 2005 the Noguchi Memorial Institute for Medical 
Research (NMIMR), in collaboration with the National 
Malaria Control Programme (NMCP), has been moni-
toring the therapeutic efficacy of first-line anti-malarial 
drugs from sentinel sites across Ghana with the view of 
providing continuous data to inform malaria treatment 
policy in the country. This paper covers the therapeutic 
efficacy of AS-AQ and AL across two ecological zones in 
Ghana during the period July 2013 to March 2014 using 




The study was a one-arm prospective evaluation of the 
clinical, parasitological, and haematological responses to 
directly observed therapy for uncomplicated malaria with 
either AS-AQ or AL among children aged 6  months to 
9  years in sentinel sites representing the savannah and 
forest zones of Ghana. The primary objective of the study 
was to assess cure rates in the two ecological zones whilst 
secondary objectives were to assess patterns of fever and 
parasite clearance as well as changes in haemoglobin lev-
els and gametocyte carriage rates after treatment with 
AS-AQ and AL.
Study sites
Therapeutic efficacy of AS-AQ was studied in the Yendi 
Municipal and Wa Regional Hospitals (representing the 
savannah zone) and Hohoe Municipal Hospital (repre-
senting the forest zone). Therapeutic efficacy of AL was 
studied in Navrongo War Memorial Hospital (repre-
senting the savannah zone) and Bekwai Municipal and 
Begoro District Hospitals (representing the forest zone).
The Yendi Municipal is located in the Northern region 
of Ghana with an estimated municipal population of 
117,780 and an annual average rainfall of 1125 mm. Wa 
regional hospital is located within Wa municipal in the 
Upper West region of Ghana with an estimated munici-
pal population of 107,214 and an annual average rainfall 
of between 840  mm and 1400  mm. The Navrongo War 
Memorial Hospital is located in the Kassena Nakana 
East district in the Upper East region of Ghana with an 
estimated district population of 109,944 and an annual 
average rainfall of 950  mm. Malaria transmission in 
the savannah zone of Ghana is generally perennial with 
marked seasonal variation and an annual entomologi-
cal rate of about 418 infective bites per person per year 
[9–11, 13–15].
Hohoe is located in the Volta region of Ghana with 
an estimated municipal population of 262,046 and an 
annual average rainfall of 1300 mm. The rainfall pattern 
is bimodal with two distinct rainy seasons: April to July 
as major and September to November as minor. Malaria 
transmission in the municipality is intense and peaks 
with the two rainy seasons. Bekwai municipal is located 
in the Ashanti region of Ghana with an estimated munic-
ipal population of 118,024. Annual rainfall in the munici-
pality is 1600–1800 mm with double maxima rainfall in 
May and October each year. Malaria transmission in the 
municipality is intense and perennial. Begoro is located 
in the Fanteakwa district in the Eastern region of Ghana. 
The Fanteakwa district has an estimated population of 
108,614. Annual rainfall in the district is 1500–2000 mm 
with double maxima rainfall in June and October each 
year. Malaria transmission in the district is intense and 
perennial. Annual entomological inoculation rate in the 
forest zone can be as high as 866 infective bites per per-
son per year [9, 10, 12, 16–18].
Study population
Children aged between 6 months and 9 years with a his-
tory of fever suggestive of malaria were screened for the 
study. Blood samples from a finger prick were used to 
prepare thick and thin smears for malaria microscopy 
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and haemoglobin level determination. Children who met 
the inclusion criteria were recruited into the study after 
parental consent had been obtained. Inclusion criteria 
included axillary temperature ≥37.5 °C or history of fever 
during the past 24  h; mono-infection with Plasmodium 
falciparum; parasite count ranging between 1000 and 
250,000 per µl; haemoglobin level >5 g/dl; and absence of 
signs/symptoms of severe malaria.
Treatment
All anti-malarials used in the study were fixed-dose com-
binations, and were supplied by the WHO, Geneva. For 
sites studying AS-AQ, children enrolled received sin-
gle daily weight-based products from Sanofi Aventis. 
The products were 25/67.5  mg (batch number 1084, 
expiring 01/2015) for children weighing 4.5 to  <9  kg; 
50/135  mg (batch number 3109, expiring 02/2015) for 
children weighing 9 to  <18  kg; and 100/270  mg (batch 
number 5433, expiring 01/2015) for children weighing 
18 to  <36  kg. For sites studying AL, children enrolled 
received weight-based 20/120  mg of Coartem® (batch 
number F0785, expiring 05/2014) at 0, 8, 24, 36, 48, and 
60 h. Children weighing 5 to <15 kg were given one tablet 
per hour of treatment; those weighing 15 to <25 kg were 
given two tablets per hour of treatment; and those weigh-
ing 25 to  <35  kg were given three tablets per hour of 
treatment. All tablets were dissolved in water and given 
under direct observation by a study nurse and children 
were observed for 30 min to ascertain retention of anti-
malarial. Children who vomited during the observation 
period were re-treated with the same dose of anti-malar-
ial and observed for an additional 30 min. Children with 
repeated vomiting were given parenteral therapy with 
quinine as per national standard treatment guidelines 
and excluded from the study. All children were allowed 
use of antipyretics. Children who showed signs/symp-
toms of severe malaria were withdrawn from the study.
Patient follow‑up
Children enrolled into the study were followed-up for 
28 days. Children were seen at the outpatient department 
on days 1, 2, 3, 7, 14, 21, and 28 (day of commencement 
of treatment was counted as day 0). At each follow-up 
visit, the children were clinically examined by a study 
Physician, who recorded findings on a Case Record Form 
(CRF). Parasitaemia levels (asexual and sexual) were 
assessed on days 2, 3, 7, 14, 21, 28, and any day within 
the 28-day follow-up period that a child is brought to 
the clinic with fever. Thick and thin smears were stained 
with 3 % Giemsa for 30–45 min for quantification of asex-
ual parasites against 200 white blood cells using a hand 
tally counter. Sexual parasite counts were done per 1000 
white blood cells. Parasitaemia levels were expressed per 
µl blood assuming white blood cell count of 8000 per µl 
blood. A smear was declared negative when examina-
tion of 100 thick-film fields did not show presence of 
asexual parasites. For quality control purposes, all blood 
slides were read by two qualified independent micros-
copists, and discordant readings were re-examined by a 
third qualified independent microscopist. Discordance 
was defined as differences between the first and second 
microscopists regarding presence/absence of asexual or 
sexual parasites; species diagnosis; and day 0 counts meet-
ing the inclusion criterion of 1000–250,000 per µl blood. 
The first or second reading was taken as final depending 
on whichever agrees with the third reading. Filter paper 
blots were obtained on day 0 and at recurrence of para-
sitaemia for PCR genotyping. Merozoite surface proteins 
1 and 2 (msp1, msp2), and glutamate-rich protein (glurp) 
were used to distinguish between re-infection and recru-
descence [19]. Haemoglobin levels were assessed for all 
study children on days 0, 14, and 28 using an automated 
haematology analyzer (Sysmex KX-21N™).
Data analysis
Per protocol analysis was used to assess treatment out-
comes on day 28 for the two ecological zones based on 
the WHO 2009 criteria: Early treatment failure (ETF), 
Late Parasitological Failure (LPF), Late Clinical Fail-
ure (LCF), and Adequate Clinical and Parasitological 
Response (ACPR) [8]. Kaplan–Meier survival analysis 
was used to assess the cumulative incidence of treat-
ment success over the 28-day follow-up period. Sec-
ondary outcomes were patterns of fever and parasite 
clearance assessed for the two ecological zones using 
proportions (with 95 % CI) of children febrile/with tem-
perature ≥37.5 °C or parasitaemic within the first week of 
follow-up. Haematological responses were also assessed 
using pre- and post-treatment mean haemoglobin levels 
on days 0, 14 and 28. Proportions were compared using 
Chi square and Fisher’s exact tests. Normally distrib-
uted variables were compared using Student’s t test while 
skewed distributions such as parasite counts were log 
transformed before using the normal approximation. Dif-
ferences were considered significant at p < 0.05.
Ethics
The Institutional Review Board of the Noguchi Memo-
rial Institute for Medical Research, University of Ghana, 
reviewed and approved the study. Written informed con-
sent was obtained from each parent/guardian at the start 
of the study. Each parent/guardian was informed of the 
objectives, methods, anticipated benefits and potential 
hazards of the study. They were also informed that they 
were at liberty to withdraw their children from the study 
at any time without penalty.
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Results
Baseline characteristics
A cumulative total of 310 children participated in the 
study in the two ecological zones: 140 received AS-AQ 
and 170 received AL. Of the children who received 
AS-AQ, 81 (57.9  %) were within the savannah zone. Of 
the children who received AL, 124 (72.9  %) were in the 
forest zone. For both anti-malarials, there were no sig-
nificant differences between the two ecological zones, in 
terms of male/female ratio as well as baseline mean hae-
moglobin levels (Tables  1, 2). The majority of children 
who received AS-AQ were aged 5–9  years in the forest 
zone (55.9 %; 95 % CI 42.5, 68.6) and less than 5 years in 
the savannah zone (69.1  %; 95  % CI 57.8, 78.7). For the 
same group of children, mean axillary temperature was 
significantly higher in the savannah zone compared with 
the forest zone whilst geometric mean parasite count was 
significantly higher in the forest zone (Table  1). Among 
children who received AL, there were no significant dif-
ferences in baseline characteristics between the two 
ecological zones. No child receiving AL was reported to 
have taken any anti-malarial within the 14-day period 
preceding visit to the clinic (Table  2). However, twelve 
children who received AS-AQ in the savannah zone were 
reported to have taken an anti-malarial within the same 
period preceding their visit to the clinic (14.8 %; 95 % CI 
8.2, 24.8) (Table 1). Intake of anti-malarial drugs among 
the twelve children was reported to have been stopped 
between 1 and 11  days prior to their visit to the clinic; 
mean number of days being 6.0 (±3.6). None of the 
children who received AS-AQ in the two ecological zones 
was gametocytaemic at baseline. Among children who 
received AL, none in the savannah zone and 4 (3.3 %) in 
the forest zone were gametocytaemic at baseline.
Primary outcomes
Per protocol treatment outcomes on day 28 were assessed 
for a total of 278 evaluable children. Out of this, 125 
received AS-AQ, and 153 received AL (Table  3). PCR-
uncorrected analyses showed an overall day 28 cure rate 
of 97.6 % (95 % CI 93.1, 99.5) for AS-AQ: 98 % (95 % CI 
89.4, 99.9) in the forest zone and 97.3  % (95  % CI 90.7, 
99.7) in the savannah zone. The overall PCR-uncorrected 
cure rate for AL was 79.1  % (95  % CI 71.8, 85.1): 85  % 
(95 % CI 77.5, 90.9) in the forest zone and 56.3 % (95 % CI 
37.7, 73.6) in the savannah zone. PCR-corrected analyses 
showed an overall cure rate of 100 % (95 % CI 96.2, 99.9) 
for AS-AQ and 97.6 % (95 % CI 93.1, 99.5) for AL. Within 
the forest zone, PCR-corrected cure rate was 100  % 
(95 % CI 90.9, 99.8) for AS-AQ and 97.2 % (95 % CI 92.0, 
99.4) for AL. Within the savannah zone, PCR-corrected 
cure rates for AS-AQ and AL were both 100 % (Fig. 1). 
No early treatment failure (ETF) was observed following 
treatment with AS-AQ or AL.
PCR-uncorrected Kaplan–Meier survival analysis 
for AS-AQ showed cumulative treatment success inci-
dence of 1.000 for the two ecological zones until day 7, 
when the incidence of success declined to 0.987 (95 % CI 
0.917, 0.999) in the savannah zone and remained 1.000 
in the forest zone (p  =  0.895). Incidence of treatment 
Table 1 Demographic, clinical, parasitological, and  haematological characteristics of  patients treated with  AS-AQ 
at baseline
a Standard deviation
b Six children had taken AS-AQ and the other six had taken AL within the 14-day period preceding their visit to the clinic
Characteristic Total (n = 140) Ecological zone p value
Forest (n = 59) Savannah (n = 81)
Male/female 74/66 29/30 45/36 0.563
Age group
 <5 years 82 (58.6 %) 26 (44.1 %) 56 (69.1 %) 0.005
 5–9 years 58 (41.4 %) 33 (55.9 %) 25 (30.9 %)
Axillary temperature in °C
 Mean temperature (sd)a 37.8 (0.9) 37.5 (0.1) 38.1 (1.1) 0.000
 Range (min, max) 35.2, 40.0 36.9, 37.5 35.2, 40.0
Parasitaemia/µl
 Geometric mean 32,479 44,669 25,750 0.001
 Range (min, max) (1000, 228,040) (1000, 228,040) (1029, 170,840)
Haemoglobin level in g/dl
 Mean (sd)a 8.7 (1.6) 8.7 (1.0) 8.7 (1.9) 1.000
 Range (min, max) (5.4, 13.9) (6.0, 13.9) (5.4, 13.9)
Previous anti‑malarial intake 12 (8.6 %) 0 12 (14.8 %)b 0.005
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success with AS-AQ remained 1.000 and 0.987 in the 
forest and savannah zones, respectively until day 21, 
when both zones experienced a decline to 0.981 (95  % 
CI 0.884, 0.999) and 0.974 (95 % CI 0.902, 0.996), respec-
tively (p  =  0.721), and remained same between day 21 
and day 28. For AL, PCR-uncorrected treatment success 
remained 1.000 in the two ecological zones until day 
14 when cumulative incidence of treatment success 
declined to 0.984 (95 % CI 0.936, 0.997) in the forest zone 
and 0.929 (95  % CI 0.795, 0.981) in the savannah zone 
(p =  0.208). Cumulative incidence of treatment success 
further declined on day 21 to 0.942 (95 % CI 0.880, 0.974) 
in the forest zone and 0.667 (95 % CI 0.481, 0.815) in the 
savannah zone (p < 0.001). Cumulative incidence of treat-
ment success remained 0.942 in the forest zone until day 
26, when it declined to 0.934 (95 % CI 0.870, 0.969), and 
further declined to 0.851 (95 % CI 0.772, 0.907) on day 28 
compared with 0.601 (95 % CI 0.422, 0.766) on the same 
day in the savannah zone (p = 0.004) (Fig. 2). PCR-cor-
rected Kaplan–Meier survival analyses showed a cumula-
tive treatment success incidence of 0.979 (95 % CI 0.935, 
0.993) for AL, translating into a cumulative treatment 
failure incidence of 0.021 (95 % CI 0.007, 0.065), and no 
treatment failure for AS-AQ.
Secondary outcomes
Generally, prevalence of fever decreased by about 75  % 
after first day of treatment with each ACT (26.4 %; 95 % 
CI 19.5, 34.7 for AS-AQ and 21.4 %; 95 % CI 15.6, 28.6 for 
AL; p = 0.372) (Fig. 3). For AS-AQ, only one child in the 
savannah zone was reported to have had fever on day 7 
(1.2 %; 95 % CI 0.1, 8.0). This child was, however, apara-
sitaemic and remained same throughout the rest of the 
follow-up period. No child was febrile in the forest zone 
on day 7. For AL, no child was febrile on day 7 in the two 
ecological zones.
No child in the two ecological zones was parasitae-
mic on day 3 (Fig. 4). For AS-AQ, only one child in the 
Table 2 Demographic, clinical, parasitological, and haematological characteristics of patients treated with AL at baseline
a Standard deviation
Characteristic Total (n = 170) Ecological zone p value
Forest (n = 124) Savannah (n = 46)
Male/female 77/93 56/68 21/25 0.907
Age group
 <5 years 110 (64.7 %) 81 (65.3 %) 29 (63.0 %) 0.924
 5–9 years 60 (35.3 %) 43 (34.7 %) 17 (37.0 %)
Axillary temperature in °C
 Mean temperature (sd)a 38.1 (1.0) 38.2 (1.0) 37.9 (1.1) 0.093
 Range (min, max) 35.6, 40.2 35.6, 40.2 35.9, 40.1
Parasitaemia/µl
 Geometric mean 39,983 38,665 43,766 0.415
 Range (min, max) (1080, 240,840) (1080, 239,890) (1280, 240,840)
Haemoglobin level in g/dl
 Mean (sd)a 10.2 (1.5) 10.2 (1.6) 10.3 (1.2) 0.695
 Range (min, max) (5.6, 14.4) (5.6, 13.1) (6.4, 14.4)
Table 3 Per protocol day-28 treatment outcomes (PCR-
uncorrected) for  AS-AQ and  AL by  two ecological zones 
in Ghana
a Not assessed
b One was withdrawn on day 2 because she was generally weak. Eight were lost 
to follow-up: four on day 7; two on day 14; and two on day 21
c All lost to follow-up: three on day 3; two on day 7; and one on day 14
d One was withdrawn on day 0 because of excessive vomiting after intake of 
medicine. One each was lost to follow-up on days 1 and 2







AS‑AQ n = 140 n = 59 n = 81
ETF 0 0 0
LCF 1 1 0
LPF 2 0 2
ACPR 122 49 73
NAa 15 9b 6c
AL n = 170 n = 124 n = 46
ETF 0 0 0
LCF 8 8 0
LPF 24 10 14
ACPR 121 103 18
NAa 17 3d 14e
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savannah zone was parasitaemic on day 7 (1.3 %; 95 % CI 
0.1, 7.9) as against none in the forest zone. The child who 
had malaria parasites on day 7 was confirmed by PCR to 
be a case of re-infection. For AL, no child was parasitae-
mic on day 7.
Prevalence of gametocytaemia remained less than 5 % 
during the 28-day follow-up period after treatment with 
AS-AQ and AL in the two ecological zones. For AS-AQ, 
gametocytaemia was absent in the forest zone dur-
ing the entire follow-up period. Gametocytaemia in the 
savannah zone was 1.3 % (95 % CI 0.1, 7.7) on days 2 and 
3 after treatment with AS-AQ, and remained absent from 
day 7 to day 28. For AL, gametocytaemia in the forest 
zone declined from 3.3 % (95 % CI 1.1, 8.6) on day zero 
to 0.9 % (0.1, 5.5) on day 28 (p = 0.413), and was present 
only on day 7 (2.4  %; 95  % CI 0.1, 4.4) in the savannah 
zone.
Fig. 1 Per protocol PCR‑uncorrected and PCR‑corrected cure rates 
for AS‑AQ and AL in two ecological zones in Ghana. Colour blue is 
PCR‑uncorrected data whilst dark red is PCR‑corrected data
Fig. 2 PCR‑uncorrected Kaplan–Meier survival curve for AS‑AQ and 
AL in two ecological zones in Ghana. Dark blue line with diamond 
spots represents AS‑AQ in the forest zone; dark red line with square 
spots represents AS‑AQ in the savannah zone; green line with delta 
spots represents combined or overall AS‑AQ data (for both savannah 
and forest zones); purple line with (X) spots represents AL in the forest 
zone; light blue line with (*) spots represent AL in the savannah zone; 
and orange line with circular spots represents combined or overall AL 
data (for both savannah and forest zones)
Fig. 3 Proportion of children with fever during first week of follow‑
up by ecological zone. Dark blue line with diamond spots represents 
AS‑AQ in the forest zone; dark red line with square spots represents 
AS‑AQ in the savannah zone; green line with delta spots represents 
combined or overall AS‑AQ data (for both savannah and forest zones); 
purple line with (X) spots represents AL in the forest zone; light blue line 
with (*) spots represent AL in the savannah zone; and orange line with 
circular spots represents combined or overall AL data (for both savan‑
nah and forest zones)
Fig. 4 Proportion of children with parasites during first week of 
follow‑up by ecological zone. Dark blue line with diamond spots 
represents AS‑AQ in the forest zone; dark red line with square spots 
represents AS‑AQ in the savannah zone; green line with delta spots 
represents combined or overall AS‑AQ data (for both savannah and 
forest zones); purple line with (X) spots represents AL in the forest zone; 
light blue line with (*) spots represent AL in the savannah zone; and 
orange line with circular spots represents combined or overall AL data 
(for both savannah and forest zones)
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Mean haemoglobin concentration in the forest zone 
significantly increased from 8.7 (±1.0) at baseline to 9.2 
(±0.8) on day 28 after treatment with AS-AQ (p = 0.006). 
Similarly, mean haemoglobin concentration in the same 
zone significantly increased from 10.2 (±1.6) at base-
line to 10.7 (±1.3) on day 28 after treatment with AL 
(p = 0.011). Within the savannah zone, mean haemoglo-
bin concentration significantly increased from 8.7 (±1.9) 
at baseline to 10.3 (±2.1) after treatment with AS-AQ 
(p < 0.001) (Table 4).
Discussion
The therapeutic efficacy of two of Ghana’s first-line anti-
malarial drugs for the treatment of uncomplicated malaria 
(AS-AQ and AL) were studied in six sentinel sites repre-
senting the forest and savannah zones during the 2013/2014 
surveillance period, with the view of providing information 
to guide malaria treatment policy in the country.
The study showed that PCR-uncorrected cure rates 
for AS-AQ were 98 % (95 % CI 89.4, 99.9) in the forest 
zone and 97.3 % (95 % CI 90.7, 99.7) in the savannah zone 
whilst AL showed PCR-uncorrected cure rates of 85  % 
(95 % CI 77.5, 90.9) in the forest zone and 56.3 % (95 % 
CI 37.7, 73.6) in the savannah zone. Although the study 
was not a comparative study, the findings compare well 
with the observation of higher PCR-uncorrected cure 
rate for AS-AQ, compared with AL, in Mozambique [20]. 
This observation may be explained by the longer termi-
nal half-life of amodiaquine (approximately 10  days) 
over lumefantrine (approximately 4  days) resulting in a 
higher post-treatment prophylactic effect of AS-AQ [21, 
22]. This notwithstanding, PCR-corrected cure rates for 
AS-AQ and AL were comparable in the forest and savan-
nah zones of Ghana (100 % for AS-AQ and 97.2–100 % 
for AL) as in other studies [5, 22–26].
Both AS-AQ and AL achieved effective fever and par-
asite clearance in the two ecological zones. Prevalence 
of fever in both zones declined by 75  % after first day 
of treatment with each ACT; no child was parasitaemic 
on day 3; and prevalence of gametocytaemia generally 
declined from 3.3 to 0.9  % within the 28-day follow-up 
period. These findings suggest that ACT still has a rapid 
effect on fever and parasite clearance as well as gameto-
cyte carriage in Ghana [5, 23, 27, 28]. Absence of parasi-
taemia on day 3 is an indication that Ghana is currently 
free of artemisinin resistance based on WHO’s indicator 
of day 3 parasitaemia of ≥10 % [29].
Post-treatment mean haemoglobin concentrations 
assessed on day 28, compared with pre-treatment con-
centrations, showed significant increase with both 
AS-AQ and AL treatment in the forest zone, and AS-AQ 
in the savannah zone (there was no available post-treat-
ment data for AL treatment in the savannah zone). These 
findings suggest that ACT treatment for uncomplicated 
malaria has a positive effect on post-treatment haemo-
globin levels. Though some studies have not shown sig-
nificantly improved post-treatment haemoglobin levels 
after ACT treatment [26, 28, 30], others have [5, 27, 31].
Conclusions
Therapeutic efficacy of AS-AQ and AL remains over 
90 % in the forest and savannah zones of Ghana. The two 
drugs were effective in clearing fever and parasites as well 
as maintaining gametocytaemia at low rates (less than 
5  %), and improving post-treatment mean haemoglobin 
levels. Artemisinin is still efficacious in Ghana by virtue 
of the absence of parasitaemia on day 3 post-treatment.
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Table 4 Changes in  mean haemoglobin levels after  treat-
ment with AS-AQ and AL in two ecological zones in Ghana
** Not available
Anti‑malarial Ecological zone
Forest p value Savannah p value
AS‑AQ Day 0 mean Hb (sd) 8.7 (1.0) 0.295 8.7 (1.9)
Day 14 mean Hb (sd) 8.9 (1.0) 0.006 9.6 (1.8) 0.002
Day 28 mean Hb (sd) 9.2 (0.8) 10.3 (2.1) <0.001
AL Day 0 mean Hb (sd) 10.2 (1.6) 10.3 (1.2)
Day 14 mean Hb (sd) 10.4 (1.3) 0.299 **
Day 28 mean Hb (sd) 10.7 (1.3) 0.011 **
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